Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S Sydnor
Modelling the Effectiveness of Ibrutinib Versus Physician’s Choice (PC) in Relapsed or Refractory (RR) Waldenström’s Macroglobulinemia (WM) Within England
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Cost-Effectiveness of Ibrutinib in Patients With Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Waldenstrom Macroglobulinemia: Evidence for a Graft-Versus-Lymphoma Effect
Haematologica
Hematology
Update in Waldenström’s Macroglobulinemia
Cancer therapy & Oncology International Journal
Atacicept in Relapsed/Refractory Multiple Myeloma or Active Waldenström's Macroglobulinemia: A Phase I Study
British Journal of Cancer
Cancer Research
Oncology
PATIENT-REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB-RITUXIMAB IN THE INNOVATE STUDY
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Idelalisib in a Patient With Refractory Waldenström’s Macroglobulinemia Complicated by Anuric Renal Failure: A Case Report
Journal of Medical Case Reports
Medicine
Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma
American Journal of Hematology
Hematology
Phase Ib/Ii Study of Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
